Marci English, head of biopharma and ophthalmology development at Astellas Pharma, said the FDA's change of heart will "further [solidify] Izervay's status as a trusted choice for thousands of GA ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Astellas Pharma has agreed its largest-ever acquisition, buying US biotech Iveric Bio in a deal that continues to build its presence in the ophthalmology sector, The $40-per-share offer values ...

BERLIN, February 17, 2025--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for the ...

We believe that the need for pharma companies to replenish their medium-term product pipelines with innovative assets makes NOX-A12 an attractive opportunity for potential partners looking to ...

DOC Pharma strengthens its offerings with the acquisition of the Geopharma nutraceuticals portfolio, and the closing of the previously announced acquisition of Muscoril® New brand identity ...

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancer by targeting the tumor microenvironment (TME), ...

Sanofi S.A. Part Cert 0.02% €8.03M ...

IPC Indice de Precios Y Cotizaciones 54,476.74 185.10 0.34% ...

Bonus Mar 07, 2000 Apr 01, 2000 Feb 22, 2000 Bonus Ratio: 1 share(s) for every 1 shares held Bonus Oct 26, 1998 Nov 19, 1998 Oct 08, 1998 Bonus Ratio: 1 share(s) for every 1 shares held Aurobindo ...

Natco Pharma Ltd., incorporated in the year 1981, is a Mid Cap company (having a market cap of Rs 14,561.63 Crore) operating in Pharmaceuticals sector. Natco Pharma Ltd. key Products/Revenue Segments ...